Appeals court affirms decision to place a hold on the Biden administration's COVID-19 vaccine mandate for large employers; rising Medicare premiums linked with controversial Alzheimer drug; 3 states expand COVID-19 booster shot eligibility to all adults.
Despite arguments from the Department of Justice saying that requirements for large companies to adhere to COVID-19 vaccination or weekly testing and mask wearing were necessary and had legal standing, on Friday an appeals court affirmed its ruling to keep the mandate on hold. Reported by Reuters, the 3-member panel of the US Court of Appeals for the Fifth Circuit, in New Orleans, noted in its ruling that the mandate was overbroad and did not account for differences in workplaces and workers. Other challenges to the mandate remain in other Circuit courts, with the Supreme Court expected to eventually decide the matter.
As reported by The Hill, premiums for seniors on Medicare will increase by more than $20 per month next year, with the controversial Alzheimer drug aducanumab cited as a major contributing factor to the rise in cost. As one of the largest increases in recent years, the Biden administration announced Friday that Medicare Part B premiums will increase by $21.60, from $148.50 in 2021 to $170.10 in 2022. Half of the increase was indicated to be due to contingency planning for financing the Alzheimer drug, which costs $56,000 per year. Administration officials said that the growth in costs will be greatly offset by large cost-of-living increases given to Medicare recipients in their Social Security payments next year.
Amid growing research suggesting a waning protection for people vaccinated against SARS-CoV-2 and a rising trend in breakthrough cases, CBS News reports that California, Colorado, and New Mexico have expanded eligibility for booster shots to all adults aged 18 and older. With booster access currently available for seniors and other high-risk individuals, the decision by the 3 states, who have some of the highest rates of new COVID-19 infections nationwide, will be in defiance of the FDA and CDC recommendations. Other states were noted to be considering lifting age restrictions as well.
Integrating RECIST and Clinician Approaches Boosts NSCLC Research
May 8th 2024Outcomes among patients with stage IV non–small cell lung cancer as evaluated within clinical trials via Response Evaluation Criteria in Solid Tumors (RECIST) and clinician response criteria in observational studies were compared for their concordance and reliability.
Read More
CMS Medicare Final Rule: Advancing Benefits, Competition, and Consumer Protection
May 7th 2024On this episode of Managed Care Cast, we're talking with Karen Iapoce, senior director of government products and programs at ZeOmega, about the recent CMS final rule on Medicare Part D and Medicare Advantage.
Listen
The Joint Commission is launching the Rural Health Clinic Accreditation Program to standardize staff training and patient care practices at rural health clinics nationwide; the American Cancer Society recently launched the largest-ever study of cancer risk and outcomes in Black women; the HHS COVID-19 vaccination campaign saved $732 billion by preventing illness and related costs.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
AA Unlikely to Cause Anxiety, Depression but May Be Affected by Mental Illness
May 7th 2024A Mendelian randomization study using genetic analysis found that alopecia areata (AA) increases the risk of anxiety and depression, but not the other way around, providing unique evidence for a causal link while adding to existing evidence.
Read More
Integrating RECIST and Clinician Approaches Boosts NSCLC Research
May 8th 2024Outcomes among patients with stage IV non–small cell lung cancer as evaluated within clinical trials via Response Evaluation Criteria in Solid Tumors (RECIST) and clinician response criteria in observational studies were compared for their concordance and reliability.
Read More
CMS Medicare Final Rule: Advancing Benefits, Competition, and Consumer Protection
May 7th 2024On this episode of Managed Care Cast, we're talking with Karen Iapoce, senior director of government products and programs at ZeOmega, about the recent CMS final rule on Medicare Part D and Medicare Advantage.
Listen
The Joint Commission is launching the Rural Health Clinic Accreditation Program to standardize staff training and patient care practices at rural health clinics nationwide; the American Cancer Society recently launched the largest-ever study of cancer risk and outcomes in Black women; the HHS COVID-19 vaccination campaign saved $732 billion by preventing illness and related costs.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
AA Unlikely to Cause Anxiety, Depression but May Be Affected by Mental Illness
May 7th 2024A Mendelian randomization study using genetic analysis found that alopecia areata (AA) increases the risk of anxiety and depression, but not the other way around, providing unique evidence for a causal link while adding to existing evidence.
Read More
2 Commerce Drive
Cranbury, NJ 08512